ECACC partnerships: accessing cell lines of medical and clinical importance 

As a not-for-profit publically accessible organisation, ECACC is constantly striving to improve the range of cell lines in its collection to best reflect the needs of life science research. We actively encourage scientists and researchers from academic and commercial organisations, to deposit their cell lines with us. Not only does this ensure that the cell lines are properly curated, authenticated and quality controlled, it keeps the collection up-to-date and maintains relevance for research into infectious diseases and non-infectious diseases, such as cancer and diabetes.

This month we highlight cell lines available from two of our depositors: Cambridge Enterprise and the Medical Research Council (MRC).

Cambridge Enterprise 

As part of the University of Cambridge, Cambridge Enterprise supports academics and researchers from the University to attain knowledge-transfer and research impact. A variety of cell lines and hybridomas produced at the university have been deposited with ECACC, including the KARPAS cell lines (human, non-Hodgkin’s disease) for oncology research, hybridomas used in immunology research and HeLa-Mitotrap cell lines. Learn more about Cambridge Enterprise. 

Medical Research Council 

MRC, part of UK Research and Innovation (UKRI), works closely with the NHS and the UK health departments to deliver high priority research to advance clinical practice and improve population health. The MRC has deposited a wide range of hybridoma clones that produce a wide range of monoclonal antibodies and several mouse myeloma cell lines (for use in the research and production of therapeutic biologics) into the ECACC collection. Learn more about The Medical Research Council (MRC). 

For information on other organisations that have deposited cell lines with ECACC, visit our depositors page.

Information on how to deposit your cell lines with ECACC  can be found on our catalogue deposits page.